Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 01, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocation awards for Non-Executive Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director compensation and does not contain financial performance data.
Material Changes
On June 30, 2008, Non-Executive Directors were provisionally allocated awards over Ordinary shares and American Depository Shares (ADSs) for the service period of April 1, 2008, to June 30, 2008. The allocation prices were set at £11.18 per Ordinary share and $44.17 per ADS. The Company and Directors were informed of these allocations on July 1, 2008.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Allocation Date: June 30, 2008 (provisional allocation).
- Notification Date: July 1, 2008.
- Share Prices: Ordinary shares at £11.18; ADSs at $44.17.
- Recipients: Awards were distributed to ten Non-Executive Directors, including Sir Christopher Gent, Prof. Sir Roy Anderson, and Dr. Stephanie Burns.
- Regulatory Basis: Filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.